Hot Investor Mandate: Large Manufacturer Actively Seeks Strategic Partnerships With Therapeutics Companies, Including Platform Technologies in CVD, Metabolic Disease, and More

3 Aug

A firm that is a division of a Japan-based manufacturer of various goods including pharmaceuticals, chemicals, etc. – one of the largest privately held companies in Japan – is actively looking for global partnering opportunities that complement the firm’s current research pipeline. Types of partnerships can include in-licensing, co-development, co-commercialization, and potentially more. Though the firm is capable of making investments and may expand upon their methods of partnering with early-stage companies, the firm does not currently have a dedicated venture capital fund.

The firm is primarily interested in therapeutics that complement the firm’s current research pipeline which includes assets in cardiovascular disease, metabolic disease, peripheral arterial disease, and pain management. The firm is interested in novel compounds that they can develop through proof of concept, and is generally stage agnostic. While the firm has historically focused on small molecules, the firm has a growing interest in antibodies and cell therapies. In addition, the firm is strongly interested in platform technologies.

The firm does not have specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a comment